249 related articles for article (PubMed ID: 20007956)
1. Screening for colorectal cancer: flexible sigmoidoscopy and faecal occult blood immunochemical testing. Which test is superior?
Castiglione G
Gut; 2010 Jan; 59(1):9-10. PubMed ID: 20007956
[No Abstract] [Full Text] [Related]
2. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.
Berry DP; Clarke P; Hardcastle JD; Vellacott KD
Br J Surg; 1997 Sep; 84(9):1274-6. PubMed ID: 9313712
[TBL] [Abstract][Full Text] [Related]
4. Screening for rectal cancer.
St John DJ
Hepatogastroenterology; 2000; 47(32):305-9. PubMed ID: 10791177
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
[TBL] [Abstract][Full Text] [Related]
6. Flexible sigmoidoscopy versus fecal occult blood testing for colorectal cancer screening in asymptomatic individuals.
Stern C
Clin J Oncol Nurs; 2014 Aug; 18(4):471-2. PubMed ID: 25095304
[TBL] [Abstract][Full Text] [Related]
7. Is the type of test used for mass colorectal cancer screening a determinant of compliance? A cluster-randomized controlled trial comparing fecal occult blood testing with flexible sigmoidoscopy.
Federici A; Marinacci C; Mangia M; Borgia P; Giorgi Rossi P; Guasticchi G
Cancer Detect Prev; 2006; 30(4):347-53. PubMed ID: 16965874
[TBL] [Abstract][Full Text] [Related]
8. Screening for colorectal cancer.
Mandel JS
Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan.
Saito H
J Med Screen; 2006; 13 Suppl 1():S6-7. PubMed ID: 17227634
[TBL] [Abstract][Full Text] [Related]
10. [Mass screening for colorectal cancer].
Faivre J; Tazi MA; Launoy G
Rev Epidemiol Sante Publique; 1996; 44 Suppl 1():S7-14. PubMed ID: 8935859
[TBL] [Abstract][Full Text] [Related]
11. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy.
Hol L; de Jonge V; van Leerdam ME; van Ballegooijen M; Looman CW; van Vuuren AJ; Reijerink JC; Habbema JD; Essink-Bot ML; Kuipers EJ
Eur J Cancer; 2010 Jul; 46(11):2059-66. PubMed ID: 20621736
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the occult blood test in screening for colorectal neoplasms. A prospective study using flexible endoscopy.
Reilly JM; Ballantyne GH; Fleming FX; Zucker KA; Modlin IM
Am Surg; 1990 Mar; 56(3):119-23. PubMed ID: 2316930
[TBL] [Abstract][Full Text] [Related]
13. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer (Br J Surg 2008; 95: 1029-1036).
Corder AP; Iqbal M; Devaraj S
Br J Surg; 2008 Nov; 95(11):1428-9; author reply 1429. PubMed ID: 18844282
[No Abstract] [Full Text] [Related]
14. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
Lindholm E; Brevinge H; Haglind E
Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of various screening and surveillance methods in colorectal carcinoma].
Burchert A; Schmassmann A
Schweiz Med Wochenschr; 1998 Jun; 128(25):999-1011. PubMed ID: 9691335
[TBL] [Abstract][Full Text] [Related]
16. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer.
N Z Med J; 1999 Jan; 112(1080):4-6. PubMed ID: 10073156
[TBL] [Abstract][Full Text] [Related]
17. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of colorectal carcinoma. Annual hemoccult test and sigmoidoscopy every 5 years].
Rosenbaum A; Riemann JF
MMW Fortschr Med; 2000 Aug; 142(31-32):27-9. PubMed ID: 10992763
[TBL] [Abstract][Full Text] [Related]
19. [Colorectal cancer screening: immunological test for faecal occult blood preferred].
Jansen JB; van Rossum LG; Laheij RJ
Ned Tijdschr Geneeskd; 2009; 153():A474. PubMed ID: 19785842
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer test use--Maryland, 2002-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
